Early Treatment with Sotrovimab for Covid-19
- PMID: 35294998
- DOI: 10.1056/NEJMc2201606
Early Treatment with Sotrovimab for Covid-19
Comment in
-
Early Treatment with Sotrovimab for Covid-19. Reply.N Engl J Med. 2022 Apr 14;386(15):1481. doi: 10.1056/NEJMc2201606. Epub 2022 Mar 16. N Engl J Med. 2022. PMID: 35294999 No abstract available.
Comment on
-
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.N Engl J Med. 2021 Nov 18;385(21):1941-1950. doi: 10.1056/NEJMoa2107934. Epub 2021 Oct 27. N Engl J Med. 2021. PMID: 34706189 Clinical Trial.
Similar articles
-
Early Treatment with Sotrovimab for Covid-19.N Engl J Med. 2022 Apr 14;386(15):1480. doi: 10.1056/NEJMc2201606. Epub 2022 Mar 16. N Engl J Med. 2022. PMID: 35294997 No abstract available.
-
Early Treatment with Sotrovimab for Covid-19.N Engl J Med. 2022 Apr 14;386(15):1480. doi: 10.1056/NEJMc2201606. Epub 2022 Mar 16. N Engl J Med. 2022. PMID: 35294996 No abstract available.
-
Early Treatment with Sotrovimab for Covid-19. Reply.N Engl J Med. 2022 Apr 14;386(15):1481. doi: 10.1056/NEJMc2201606. Epub 2022 Mar 16. N Engl J Med. 2022. PMID: 35294999 No abstract available.
-
Sotrovimab: First Approval.Drugs. 2022 Mar;82(4):477-484. doi: 10.1007/s40265-022-01690-7. Drugs. 2022. PMID: 35286623 Free PMC article. Review.
-
[Sotrovimab in controlling SARS-CoV-2 infection].Pol Merkur Lekarski. 2022 Feb 22;50(295):48-50. Pol Merkur Lekarski. 2022. PMID: 35278299 Review. Polish.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources